Sparks commentary

Healthcare

Sparks

FDA approves Vertex’s (NASDAQ: VRTX) pain drug
Published by Arron Aatkar, PhD

The US FDA has approved Vertex’s suzetrigine, now called Journavx, for the treatment of adults with moderate-to-severe acute pain. Vertex has spent many decades in the challenging field of pain management and the approval of  Journavx represents a significant milestone in public health, especially following the opioid epidemic in the US.

 

Latest

Industrials | Comment

THEON INTERNATIONAL (AMS: THEON) – additional order intake

Healthcare | Comment

Cereno Scientific (STO: CRNO-B) enters the FN25 Index

Industrials | Comment

AAC Clyde Space (OTCQX: AAC) share issue raising SEK64.5m

Industrials | Comment

Hercules (AIM: HERC) acquire Advantage NRG for up to £15.7m

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free